About Homeobox protein PKNOX2
Homeobox protein PKNOX2 (PKNOX2) is a protein
from Homo sapiens identified by UniProt accession
Q96KN3, 472 residues long.
MolForge cross-references it against 0 known binders and
50 disease associations.
Target properties
| Protein name | Homeobox protein PKNOX2 |
| UniProt accession | Q96KN3 |
| Gene | PKNOX2 |
| Organism | Homo sapiens |
| Length | 472 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (50)
Diseases linked to this target (Open Targets).
- testosterone measurement · score 0.43
- heel bone mineral density · score 0.42
- vital capacity · score 0.32
- Testicular Germ Cell Tumor · score 0.32
- prostate carcinoma · score 0.31
- autosomal dominant compelling helio-ophthalmic outburst syndrome · score 0.30
- neurodegenerative disease · score 0.29
- brain measurement · score 0.26
- aspartate aminotransferase measurement · score 0.18
- survival time · score 0.17
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q96KN3-F1 | alphafold | PREDICTED | 60.16 | — |
Amino-acid sequence (472 residues)
MMQHASPAPA LTMMATQNVP PPPYQDSPQM TATAQPPSKA QAVHISAPSA AASTPVPSAP IDPQAQLEAD KRAVYRHPLF PLLTLLFEKC EQATQGSECI TSASFDVDIE NFVHQQEQEH KPFFSDDPEL DNLMVKAIQV LRIHLLELEK VNELCKDFCN RYITCLKTKM HSDNLLRNDL GGPYSPNQPS INLHSQDLLQ NSPNSMSGVS NNPQGIVVPA SALQQGNIAM TTVNSQVVSG GALYQPVTMV TSQGQVVTQA IPQGAIQIQN TQVNLDLTSL LDNEDKKSKN KRGVLPKHAT NIMRSWLFQH LMHPYPTEDE KRQIAAQTNL TLLQVNNWFI NARRRILQPM LDASNPDPAP KAKKIKSQHR PTQRFWPNSI AAGVLQQQGG APGTNPDGSI NLDNLQSLSS DSATMAMQQA MMAAHDDSLD GTEEEDEDEM EEEEEEELEE EVDELQTTNV SDLGLEHSDS LE
Explore Homeobox protein PKNOX2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets